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Bladder cancer is the sixth most common cancer, worldwide.
Approximately 54 000 new cases are diagnosed and over 12 000
deaths result from it annually in the USA (Parker et al, 1997). The
median survival for untreated invasive bladder cancer is 6 to 9
months for those with distant metastatic disease and 18 months
for those with locally advanced disease and/or involved regional
lymph nodes. The most active conventional single agents include
cisplatin (Yagoda et al, 1976; Merrin, 1978; Rossof et al, 1979;
Herr, 1980; Peters and MR, 1980; Oliver et al, 1981), methotrexate
(Natale et al, 1981; Oliver et al, 1984), vinblastine (Blumenreich
et al, 1982) and doxorubicin (Yagoda et al, 1977). Pooled data
from Phase II studies indicate a response rate of 30% for cisplatin
(95% CI 25–35%) and 29% for methotrexate (95% CI 23–35%)
(Yagoda, 1987). The M-VAC regimen containing methotrexate,
vinblastine, doxorubicin and cisplatin which was first reported by
Sternberg et al provided the first real improvement over single
agent treatment (Sternberg et al, 1985). The long-term follow-up
data on 203 patients who underwent treatment with the M-VAC
regimen has recently been updated. An overall response (OR) rate
of 67% was observed with a complete response (CR) rate of 23%
(Bajorin et al, 1998a). The median overall survival (OS) of the
whole group was 14.3 months. In a multi-centre phase III trial the
Intergroup compared M-VAC versus cisplatin. They found that M-
VAC was superior but at the expense of increased toxicity with
significant thrombocytopenia, and leukocytopenia of Grade 3 or 4
in 21% and 58%, respectively. Neutropenic sepsis occurred in
25% and was fatal in 3% (Loehrer et al, 1992).
Efforts have been made to find combinations that demonstrate
better efficacy than the M-VAC regimen but with reduced toxicity.
The CMV regimen consisting of cisplatin, methotrexate, and
vinblastine initially reported by Harker et al was less toxic and
showed OR of 56% and CR rate of 28%. However the median OS
was 8 months (Harker et al, 1985). Whilst other regimens utilizing
conventional agents in accelerated schedules of M-VAC or CMV
have been tried with similar benefit (Boshoff et al, 1995; Dodd et
al, 1998) the advent of new agents with activity in transitional cell
carcinoma invite the testing of novel regimens that may improve
outcomes.
Paclitaxel shows high activity as a single agent in untreated
transitional cell carcinoma of the bladder. The Eastern Co-opera-
tive Oncology Group demonstrated a 42% response rate in a Phase
II study of 26 patients (Roth et al, 1994), although in a group of 14
previously treated patients Papamichael et al found only 1 partial
response for a response rate of 7% (Papamichael et al, 1997).
Prompted by these observations our study substituted paclitaxel
for methotrexate in the CMV regimen, investigating the combina-
tion of paclitaxel with vinblastine and cisplatin in previously
untreated patients.
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Summary A phase II study to evaluate the efficacy and toxicity of the combination of vinblastine, paclitaxel and cisplatin (PVC) in previously
untreated patients with advanced transitional cell carcinoma. Chemotherapy naive patients with locally advanced or metastatic transitional
cell carcinoma received the intravenous combination of paclitaxel 175 mg/m2 over three hours followed by cisplatin 70 mg/m2 over 3 hours on
day 1 and vinblastine 3 mg/m2 as a bolus on days 1 and 8 on a 21-day cycle, to a maximum of 6 cycles. The day 8 vinblastine was omitted if
the total neutrophil count was <1.0. 15 patients (13 M, 2 F) of median age 66 (54–75) received a median of 5 cycles of treatment. There were
two complete responses (13%; 95% CI 2–40%) and five partial responses (33%; 95% CI 12–62%), for an overall response rate of 46%
(95% CI 21–73%). Responses occurred only in those with locally recurrent tumours and/or lymph nodes involved. Neutropenia at Grade 3–4
occurred in 14 of 67 cycles (21%) resulting in 7 episodes of neutropenic sepsis. Grade 3–4 thrombocytopenia was not observed. Other Grade
3 toxicity included alopecia (10 pts), diarrhoea (2 pts), constipation resulting in bowel obstruction (2 pts), nephrotoxicity (1 pt), myalgic pain
(1 pt) and peripheral neuropathy (1 pt). Six patients developed Grade 2 paraesthesia. The median time to progression was 6 months and the
median survival was 11 months. The regimen PVC was both less effective against transitional cell carcinoma and less toxic than expected.
This may reflect an inhibitory interaction between vinblastine and paclitaxel and this schedule cannot be recommended for further
investigation. © 2000 Cancer Research Campaign http://www.bjcancer.com
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Patient population
Eligible patients were between the ages of 18 and 75 years old
with histologically confirmed advanced transitional cell carcinoma
of the urothelium, bi-dimensionally measurable on physical exam-
ination, chest X-ray or computed tomography (CT) examination.
Patients had not received prior systemic chemotherapy nor had
radiotherapy in the preceding four weeks and required an ECOG
score of ≤ 2. A glomerular filtration rate >50 ml min–1 measured by
urinary creatinine clearance or EDTA clearance, and a serum
bilirubin level <25 mmol/l, WBC >3000 µ l–1 and platelet count
>100 000 µ l–1 were required. Patients with a history of prior malig-
nancy, except basal cell or squamous cell carcinoma of the skin or
in situ carcinoma of the cervix were excluded from the study.
Those patients with New York Heart Association Functional
Classification >1 were considered ineligible, and were those with
pre-existing peripheral neuropathy of WHO grade >1 or those with
active infection or other serious underlying medical condition
including prior allergic reaction to cremophor with cyclosporin or
vitamin K. Local Research Ethics Committee approval was
obtained and all participants gave written informed consent.
Baseline data
Pretreatment investigations included a physical examination,
blood investigations including full blood count (FBC), erythrocyte
sedimentation rate (ESR), renal and liver function test and
serum lactate dehydrogenase (LDH) and β human chorionic-
gonadotrophin (β hCG). A urinary 24-hour creatinine clearance or
EDTA was performed. Imaging investigations included a chest
radiograph and a CT of the abdomen and pelvis. A radionuclide
bone scan was performed only if clinically indicated or if serum
alkaline phosphatase (ALP) was elevated. In patients with locally
advanced disease cystoscopy and biopsy together with urine
cytology was performed.
Therapy
Vinblastine at a dose of 3 mg/m2 was administered as an intra-
venous bolus injection on days 1 and 8, followed on day 1 by
paclitaxel 175 mg/m2 in 500 ml of dextrose or 0.9% sodium chlo-
ride solution as an intravenous infusion over 3 hours. All patients
received dexamethasone 20 mg orally 12 and 6 hours before the
paclitaxel and chlorpheniramine 10 mg and cimetidine 300 mg
intravenously 30 minutes before the infusion. Finally following
hydration with 500 ml of 0.9% sodium chloride solution, cisplatin
70 mg/m2 in 1 l 0.9% sodium chloride was administered over two
hours. Thereafter a urine output of 100 ml/h–1 was maintained with
one litre of 0.9% sodium chloride solution containing 20 mmol of
magnesium sulphate and 40 mmol of potassium chloride over the
next 3 hours. The day 8 vinblastine dose was omitted if the
absolute neutrophil count had fallen to <1000 µ l–1. This cycle was
repeated every 21 days.
Evaluation
Response to treatment was first assessed following a minimum
of two cycles of therapy by chest radiograph or CT scan, and
assessed according to UICC criteria (Hayward et al, 1977). In
patients with progressive disease following 2 cycles of treatment
chemotherapy was discontinued. In cases with stable disease or
responses after two cycles, a total of 6 cycles of treatment was
administered.
Statistical analysis
The data were complete as of January 1999. All patients who
completed day 1 of treatment were considered assessable for
response and survival. Response duration and survival were
measured from the date of first treatment. Overall survival was
estimated by the Kaplan-Meier method and is shown in Figure 1.
RESULTS
Between March 1995 and February 1996 15 patients were treated,
of which 13 were male and two were female. The bladder was the
primary site in all cases. The median age was 66 years (range
54–73). 14 patients had previously undergone surgery, 6 having
had radical tumour resection (3 having undergone a cystectomy,
one a nephroureterectomy, one a cystoprostatectomy and one an
ileocystoplasty) and 8 having undergone transurethral resection.
One patient was deemed to have inoperable metastatic disease. Five
patients had relapsed following prior primary pelvic radiotherapy
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Figure 1 Kaplan-Meier plot of overall survival
Table 1 Patient characteristics.
Characteristic Number of patients
Age years
Median 66
Range 54–73
Sex
Male 13
Female 2
Sites of metastases
Lymph nodes 10
Bladder 6
Lungs 5
Liver 3
Pelvis 2
Bone 2
Ureter 1
Prostate 1
n = 15for TCC of the bladder. A total of 67 cycles of treatment were
administered with a median of 5 cycles per patient
(range 1–6). Patient characteristics and sites of disease are
summarized in Table 1.
Toxicity
Haematological toxicity was significant with Grade 3/4
neutropenia observed in 14 of 67 (21%) cycles with 7 resulting
episodes of neutropenic sepsis. The day 8 vinblastine dosage was
omitted in a total of 11 (16%) cycles because of low neutrophil
count. There were no episodes of thrombocytopenia greater than
Grade 2.
Non-haematological toxicity of Grade 3 or 4 included alopecia
in 10 patients, diarrhoea in 2 patients. Subacute bowel obstruction
occurred in 2 patients on their first cycle of therapy, neither of
whom received further cycles of this regimen. One patient
developed Grade 3 painful myalgia. Six patients developed
Grade 2 sensory neuropathy, but only one patient progressed to
Grade 3. Non-haematological toxicity is summarized in Table 2.
Response
All 15 patients are included in response calculations although it
was not possible to evaluate one patient because of toxicity
following cycle one. A complete remission was achieved in two
patients (13%; 95% CI 2–40%) and a partial remission in 5
patients (33%; 95% CI 12–62%). The OR rate was thus 46% (95%
CI 21–73%). 4 patients had SD at completion of treatment and 3
had PD. The trial was discontinued after 15 patients when it
became apparent that the response rate was unlikely to be superior
to that observed with the MVAC regimen. All of the responses
occurred in those with locoregional disease. Response to treatment
is summarized in Table 3.
The median time to progression for all patients was 6 months.
Two patients subsequently received further chemotherapy, 3
received radiotherapy for pelvic disease and 2 radiotherapy at
distant metastatic sites.
The median overall survival is 11 months (range 9–48 months)
as of November 1999. 14 patients have died of disease (range 9–21
months) and one patient is alive with no evidence of disease
progression at 48 months from therapy.
DISCUSSION
We observed an overall response rate in this study of 46% (95% CI
21–73%) and a median survival of 15 months in patients receiving
PVC for metastatic bladder TCC. Toxicity was manageable in all
but two patients with extensive intra-abdominal disease who
developed subacute bowel obstruction after the first cycle of
treatment.
There is increasing interest in the schedule dependency of
drug combinations involving paclitaxel. We adopted a schedule
with vinblastine administered immediately prior to paclitaxel.
Paclitaxel and vinblastine represent two classes of drug that target
tubulin. They have separate binding properties and opposing
mechanisms of action. Subsequently it has been shown in vitro
that there is sequence dependence, with increased stability of
paclitaxel-induced tubulin polymerization and concomitant
increase in cytotoxicity if the paclitaxel is preceded by vinblastine
by 48 hours (Giannakakou et al, 1998). However if administered
simultaneously there is a diminution of the paclitaxel-induced
tubulin polymerization and reduced cytotoxicity below that of
single agent treatment. Our regimen involved a close temporal
sequence of administration and this may have reduced the efficacy
of this combination.
The choice of paclitaxel dosage and duration of infusion are
also important variables in evaluating the efficacy of paclitaxel
combination regimens. We chose to give a short 3-hour infusion of
paclitaxel followed by cisplatin. There is debate over the optimal
dosage and duration of infusion of paclitaxel in the literature. Our
chosen dosage schedule of 175 mg/m2 over 3 hours on a 21-day
cycle has been shown to be active in combination with cisplatin
in carcinoma of the ovary and is associated with minimal
neurotoxicity.
A synergy has been observed between paclitaxel and cisplatin in
vitro in ovarian cell lines, provided that the paclitaxel is adminis-
tered prior to the cisplatin (Rowinsky et al, 1993; Jekunen et al,
1994). Preliminary Phase II data on the combination of paclitaxel
and cisplatin in previously untreated patients with transitional cell
carcinoma have shown higher response rates than we observed
with PVC. Burch et al administered paclitaxel 135 mg/m2 over 3
hours followed by cisplatin 70 mg/m2 on day 1 of a 21-day cycle.
They observed responses in 21 of 29 patients (OR 72%, CI
56–90%) with 10 CRs, and a median time to progression of 8
months and a median survival of 13 months (Burch et al, 1999).
Murphy et al reported 13 responses in 18 evaluable patients (OR
rate of 72%) using paclitaxel 170 mg/m2 over 24 hours followed
by cisplatin 75 mg/m2 on day 1 of a 21-day cycle (Murphy et al,
1996). In a multi-institutional ECOG study a regimen using pacli-
taxel 225 mg/m2 over 3 hours followed by cisplatin 75 mg/m2 on
day 1 of a 21-day cycle has been reported by Dreicer et al. They
have observed 13 objective responses in 20 evaluable patients
(63%, CI 42–81%) (Dreicer et al, 1998). A paclitaxel containing
triple combination, based upon the CMV regimen, consisting of
paclitaxel 200 mg/m2 over 3 hours followed by cisplatin 70 mg/m2
1614 C Mulatero et al
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Table 2 Non-haematological toxicity.
Grade
Non-haematological toxicity 01234
Alopecia 1 1 3 10 –
Peripheral neuropathy 6 1 7 3 0
Mucositis 13 0 2 0 0
Nausea and vomiting 4 6 3 1 1
Constipation 10 0 1 4 0
Infection 2 5 1 5 0
n = 15
Table 3 Response to treatment.
Best response Number Percentage
CR 2 13
PR 5 33
SD 4 27
PD 3 20
NE 1 7
Total 15 100
n = 15and methotrexate 30 mg/m2 on day 1 of a 21-day cycle has been
investigated in patients refractory to at least one line of
chemotherapy by Tu et al (Tu et al, 1995). In 25 patients an OR
rate of 40% was observed but no CRs were reported.
We cannot be sure whether the lower response rate observed in
our cohort of patients is due to schedule-dependent interactions
between the three drugs or to different selection criteria (e.g. inclu-
sion of patients who had received prior radiotherapy). Although
we observed responses in locoregional disease others have
observed major responses in all metastatic sites (Bajorin et al,
1998b) and this may simply have been a function of the smaller
numbers in our series.
Toxicity observed with this regimen was predictable and
generally manageable. All three drugs are neurotoxic and although
6 (40%) patients developed Grade 2 peripheral neuropathy only
one patient progressed to Grade 3 neuropathy. The low incidence
of severe peripheral neuropathy could be interpreted as further
evidence of an antagonistic interaction between the three drugs
when administered in this sequence and schedule.
We observed a lower than expected efficacy compared with
either established regimens such as MVAC or the two-drug
combination of paclitaxel and cisplatin. In addition there was less
toxicity to the peripheral nerves than expected, which we suggest
is consistent with the in vitro data for a schedule-dependent
antagonistic interaction between vincristine and paclitaxel.
Therefore this schedule of PVC cannot be recommended for
further investigation. Exploration with more appropriate
scheduling is necessary. However integration of paclitaxel and
other new drugs such as gemcitabine with platinum compounds as
already reported may hold more promise (Bellmunt et al, 1999;
Vaishampayan et al, 1999).
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